Other languages Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.87 ^USD	+4.73%		+0.29%	+35.24%

Apr. 26	Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 18	Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26
Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting	Apr. 18
Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting	Apr. 01
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy	Mar. 26
Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition	Dec. 11
Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer	Nov. 03
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting	Nov. 02
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Actinium Pharmaceuticals, Inc. Announces Two Posters Detailing Positive Clinical Experiences of Sites in the Pivotal Phase 3 Sierra Trial of Iomab-B	23-04-28
Actinium Pharmaceuticals, Inc. Announces Pivotal Phase 3 Sierra Study	23-04-27
Actinium Pharmaceuticals Announces Positive Phase 3 Trial Results, NCI CRADA for AML Drug Candidates - Could They Become New Standards of Care for This Deadly Disease	23-04-21
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings	23-02-14
Actinium Pharmaceuticals Signs R&D Deal With National Cancer Institute to Develop Actimab-A	23-02-06
Actinium Pharmaceuticals, Inc. Signs Cooperative Research and Development Agreement with National Cancer Institute	23-02-06
Actinium Pharmaceuticals' Phase 3 Trial Data for Iomab-B Accepted for Presentation at Medical Conference	23-01-12
Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash	22-12-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Other languages

Filters